RXRX as reported
Recursion Pharmaceuticals, Inc. reported $66M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed.
$66M
Revenue, trailing twelve months · to Q1 2026 · +11% against the twelve months before
- Net Income
- −$560M
Net Income · −2.6% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$326M
Free Cash Flow · −18% year on year · trailing twelve months to Q1 2026
- Op Margin
- −1634%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $66M | +11% | Q1 2026 |
| Net Income | −$560M | −2.6% | Q1 2026 |
| EPS | −$1.16 | −36% | Q1 2026 |
| Gross Margin | −55% | n/a | Q1 2026 |
| Op Margin | −1634% | n/a | Q1 2026 |
| Net Margin | −1537% | n/a | Q1 2026 |
| ROE | −63% | n/a | Q1 2026 |
| ROA | −47% | n/a | Q1 2026 |
| ROIC | −127% | n/a | Q1 2026 |
| Free Cash Flow | −$326M | −18% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Recursion Pharmaceuticals, Inc. (RXRX) - Revenue & ProfitRevenue & ProfitRecursion Pharmaceuticals, Inc. (RXRX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com